이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IDEXX Laboratories 관리

관리 기준 확인 3/4

IDEXX Laboratories' CEO는 Jay Mazelsky, Jun2019 에 임명되었습니다 의 임기는 4.67 년입니다. 총 연간 보상은 $ 11.52M, 8.7% 로 구성됩니다. 8.7% 급여 및 91.3% 보너스(회사 주식 및 옵션 포함). 는 MX$ 755.66M 가치에 해당하는 회사 주식의 0.099% 직접 소유합니다. 755.66M. 경영진과 이사회의 평균 재임 기간은 각각 5 년과 7.7 년입니다.

주요 정보

Jay Mazelsky

최고 경영자

US$11.5m

총 보상

CEO 급여 비율	8.7%
CEO 임기	5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	7.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jay Mazelsky 의 보수는 IDEXX Laboratories 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$867m
Dec 31 2023	US$12m	US$1m	US$845m
Sep 30 2023	n/a	n/a	US$823m
Jun 30 2023	n/a	n/a	US$791m
Mar 31 2023	n/a	n/a	US$699m
Dec 31 2022	US$10m	US$1m	US$679m
Sep 30 2022	n/a	n/a	US$670m
Jun 30 2022	n/a	n/a	US$664m
Mar 31 2022	n/a	n/a	US$735m
Dec 31 2021	US$9m	US$977k	US$745m
Sep 30 2021	n/a	n/a	US$757m
Jun 30 2021	n/a	n/a	US$728m
Mar 31 2021	n/a	n/a	US$674m
Dec 31 2020	US$7m	US$814k	US$582m
Sep 30 2020	n/a	n/a	US$497m
Jun 30 2020	n/a	n/a	US$460m
Mar 31 2020	n/a	n/a	US$437m
Dec 31 2019	US$7m	US$632k	US$428m
Sep 30 2019	n/a	n/a	US$423m
Jun 30 2019	n/a	n/a	US$407m
Mar 31 2019	n/a	n/a	US$390m
Dec 31 2018	US$3m	US$555k	US$377m
Sep 30 2018	n/a	n/a	US$330m
Jun 30 2018	n/a	n/a	US$307m
Mar 31 2018	n/a	n/a	US$284m
Dec 31 2017	US$2m	US$469k	US$263m

보상 대 시장: Jay 의 총 보상 ($USD 11.52M )은 MX 시장( $USD 5.83M ).

보상과 수익: Jay 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jay Mazelsky (63 yo)

5yrs

테뉴어

US$11,519,309

보상

Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jonathan Mazelsky	President	5yrs	US$11.52m	0.099% $ 726.4m
Brian McKeon	CFO, Executive VP & Treasurer	10.4yrs	US$3.85m	0.035% $ 260.3m
Michael Lane	Executive VP and GM of Reference Laboratories & Information Technology	4.4yrs	US$2.92m	0.0085% $ 62.7m
John Hart	Senior Vice President of Global Operations	6.8yrs	데이터 없음	데이터 없음
Jeffery Chadbourne	Senior Vice President of Commercial Finance & Sales Operations	9.4yrs	데이터 없음	데이터 없음
Martin Smith	Executive VP & CTO	2.8yrs	데이터 없음	데이터 없음
Ken Grady	Senior VP & Chief Information Officer	8.3yrs	데이터 없음	데이터 없음
Sharon Underberg	Executive VP	no data	US$1.88m	0.0068% $ 49.8m
Michael Johnson	Executive VP & Chief Human Resources Officer	2.3yrs	데이터 없음	0.00022% $ 1.6m
George Fennell	Senior VP & Chief Revenue Officer	no data	데이터 없음	0.0084% $ 61.7m
Kerry Bennett	Senior VP and GM of Product & Strategy of Global Reference Labs	less than a year	데이터 없음	데이터 없음
Michael Erickson	Executive VP and GM of Point of Care Diagnostics & Telemedicine	no data	데이터 없음	0.013% $ 95.0m

5.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: IDXX * 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jonathan Mazelsky	President	4.7yrs	US$11.52m	0.099% $ 726.4m
M. Szostak	Independent Director	11.9yrs	US$367.66k	0.0079% $ 58.5m
Daniel Junius	Independent Director	10.3yrs	US$362.66k	0.0031% $ 22.7m
Bruce Claflin	Independent Director	8.9yrs	US$367.66k	0.0021% $ 15.3m
Jonathan Ayers	Non-Employee Director	22.4yrs	US$335.16k	0.70% $ 5.2b
Stuart Essig	Independent Director	6.9yrs	US$350.16k	0.0024% $ 17.6m
Lawrence Kingsley	Independent Non-Executive Chairman	7.7yrs	US$495.02k	0.0095% $ 70.3m
Sophie Vandebroek	Independent Director	10.9yrs	US$335.16k	0.011% $ 80.2m
Irene Chang Britt	Independent Director	less than a year	US$258.89k	0.00025% $ 1.8m
Sam Samad	Independent Director	4.9yrs	US$342.66k	0% $ 0
Asha Collins	Independent Director	3.6yrs	US$335.16k	0.00094% $ 6.9m

7.7yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: IDXX * 의 이사회는 경험(평균 재직 기간 7.7 년)으로 간주됩니다.

IDEXX Laboratories 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

Recent updates

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Insufficient new directors

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold Mex$52m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Insufficient new directors

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold Mex$2.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

President recently sold Mex$81m worth of stock

Insider recently sold Mex$142m worth of stock

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Independent Director has left the company

Senior Advisor & Director recently sold Mex$5.5m worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold Mex$3.3m worth of stock

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령